Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172891 | 0.74 | HSP90AA1 (0.46) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL9771328 | 0.74 | FGFR1 (0.42) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL3272205 | 0.74 | CYP3A4 (0.53) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL544333 | 0.74 | NOS1 (0.42) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL12676747 | 0.72 | CYP11B1 (0.50) | HTTFGFR1HSP90AA1HSP90AB1CYP3A4 | |
| SCHEMBL20033972 | 0.71 | HSP90AA1 (0.51) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL10183098 | 0.71 | HSP90AA1 (0.41) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL2359179 | 0.69 | NOS1 (0.52) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL7563960 | 0.69 | ATM (0.53) | HTTFGFR1HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL5383780 | 0.69 | HSP90AA1 (0.40) | HTTFGFR1HSP90AA1HSP90AB1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029158-A | EGFR inhibitors | 缆图药品公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12610732-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-12497420-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4358685-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4650415-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025080784-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4358685-A2 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11926625-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2024029583-A1 | NOVEL PYRAZOLE DERIVATIVE AND USE OF SAME | 国立研究開発法人理化学研究所 | 2024-02-08 | — | — | WO | disclosed |
| US-20230167145-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167145-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167145-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-20230115552-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-04-13 | — | — | US | disclosed |
| CN-114380867-A | Organic electroluminescent material and device | 环球展览公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220112232-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3978583-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HTT 1147/4885FGFR1 3115/4885HSP90AA1 755/4885 |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HTT 1147/4885FGFR1 3115/4885HSP90AA1 755/4885 |
| US-20220112232-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, OR10J3 | HTT 2044/4885FGFR1 4344/4885HSP90AA1 4542/4885 |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | HTT 2755/4885FGFR1 260/4885HSP90AA1 1477/4885 |
| US-20230115552-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | HTT 2047/4885FGFR1 4087/4885HSP90AA1 4263/4885 |
| US-12610732-B2 | Organic electroluminescent materials and devices | ICOSLG, SSB, SART3 | HTT 3103/4885FGFR1 2574/4885HSP90AA1 4254/4885 |
| US-20230167145-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | HTT 2047/4885FGFR1 4087/4885HSP90AA1 4263/4885 |
| US-12497420-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OR10J3 | HTT 2044/4885FGFR1 4344/4885HSP90AA1 4542/4885 |
| US-11926625-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | HTT 1147/4885FGFR1 3115/4885HSP90AA1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.